Trial · NCT07463248
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
NCT07463248, Phase 2, Recruiting, Wang Xin
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy. Trials, record NCT07463248. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07463248
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
- NCT number
- NCT07463248
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 64 participants, estimated
- Lead sponsor
- Wang Xin
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Tislelizumab Combined With TKI, Fecal Microbiota Transplantation, PULSAR
- First posted
- 2026-03-11
- Last updated
- 2026-09-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | From randomization to the first occurrence of disease progression or death from any cause up to approximately 24 months | PFS is defined as the time from the date of randomization until the date of disease progression according to RECIST 1.1 or death by any cause. |
| Secondary | Overall Survival (OS) | From randomization to death due to any cause up to approximately 24 months | OS is defined as the time from the date of randomization until death due to any cause. |
| Secondary | Objective Response Rate (ORR) | From date of randomization until the date of first documented progression, assessed up to 24 months | ORR (per RECIST 1.1 as assessed by the Investigator) was defined as the number (%) of participants with at least 1 confirmed visit response of CR or PR until progression, or the last evaluable assessment in the absence of progression. |
| Secondary | Disease Control Rate (DCR) | From date of randomization until the date of first documented progression, assessed up to 24 months | Number (%) of participants with CR, PR, or SD. |
| Secondary | Number of participants with adverse events (AEs) | Up to 24 months | Incidence and severity of adverse events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0, vital signs, and clinical laboratory test results in the Safety Analysis Set |
| Secondary | Changes in gut microbiota indicators | At baseline (prior to FMT), first efficacy evaluation (approximately 9 weeks post-FMT), and exit from the group | Changes in patient microbiome will be determined by analysis of gut bacterial composition in patient stool samples at baseline and post-FMT. |
| Secondary | Changes in tumor immune microenvironment indicators | At baseline (prior to FMT), first efficacy evaluation (approximately 9 weeks post-FMT), and exit from the group | Effects on the patient immune microenvironment will be assessed by examining changes in peripheral blood immune cells （including CD3, CD4, CD8 T cells, B cells, macrophages, NK cells, Th1, Th2, Th17, and Treg cells）at baseline and post-FMT. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07463248
GET https://conductscience.org/api/trials/v1/NCT07463248/registered